Groundbreaking three-year partnership to tackle prostate cancer
Prostate Cancer Foundation of Australia (PCFA) and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) have agreed to a landmark three-year
xx Gift of $xx
Or enter your own donation amount
Please complete your details
* Indicates a required field
Telehealth and Teletrials
Teletrials builds on the telehealth model and increases access to clinical trials for people with cancer living in rural and remote locations.
Teleheath and Teletrials
Teletrials builds on the telehealth model and increases access to clinical trials for people with cancer living in rural and remote locations, or in self-isolation due to COVID-19. Teletrials also allows trials recruitment and activity to continue.
Congratulations! @ANZUPTrials #WOMBAT Phase 2 #ProstateCancer study has recruited their 1st patient at @GrampiansHealth PI Sharad Sharma. Well done to all involved @AnthonyMJoshua #MeganCrumbaker @georgeinstitute @Bayer @Prof_IanD @PCFA @CancerAustralia https://anzup.org.au/clinical-trial/wombat/
No sooner had our @ANZUPTrials #GDISCO (ANZUP 2403) study open at Fiona Stanley Hospital in Perth, the first participant has been recruited! Well done to all involved in this important #BladderCancer study #SMHS @CancerAustralia @Prof_IanD
Our @ANZUPTrials #GDISCO (ANZUP 2403) #BladderCancer study (Gemcitabine Docetaxel Intra-vesical Synchronous CO-administration) is officially now open at Fiona Stanley Hospital in Perth #SMHS @CancerAustralia @Prof_IanD
Good to see @ANZUPTrials #ENZAMET trial getting a mention during @ChrisSweens1 talk & panel discussion at #ACTA2024 ‘Harnessing the value of clinic-genomic data from multiple phase 3 prostate cancer trials’ @PCFA @CancerAustralia @ChrisSweens1 @Prof_IanD
2Prostate Cancer Foundation of Australia (PCFA) and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) have agreed to a landmark three-year
New research findings of the ENZAMET (ANZUP 1304) study, led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), reveal that
Lutetium-177 PSMA-617 – or LuPSMA – therapy had been shown in previous clinical trials to extend lives, and improve quality-of-life, in patients with advanced metastatic
To assess the safety of sub-urothelial injection of durvalumab and examine the impact on tissue and circulating immune cell populations.
Prostate Cancer Foundation of Australia (PCFA) and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) have agreed to a landmark three-year
New research findings of the ENZAMET (ANZUP 1304) study, led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), reveal that
Lutetium-177 PSMA-617 – or LuPSMA – therapy had been shown in previous clinical trials to extend lives, and improve quality-of-life, in patients with advanced metastatic